TheraDep Technologies has appointed Richard Fernandes as Chief Operating Officer (COO), who was former GM of Agilent Life Sciences, to lead the company’s transition from pilot programs to full-scale commercial global expansion.
Key Leadership Focus
- Commercial Scaling: Fernandes is tasked with scaling manufacturing capacity to meet the accelerating demand for the BioDep® cold-plasma coating technology.
- Operational Infrastructure: He will oversee product development, supply-chain reliability, and regulatory readiness as the company expands operations in Ireland and the United States.
- Market Alignment: His role focuses on bridging the gap between innovation and market-ready systems, ensuring high-quality, repeatable results for medical device and life-science partners.
Strategic Context
This hire marks TheraDep’s entry into a high-growth commercial phase, specifically targeting the need for physiologically relevant assays and bioactive surface functionalization.
